SARS-CoV2

3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Octapharma
OctapharmaAustria - Vienna
1 program
1
OctagamPhase 41 trial
Active Trials
NCT04411667Completed34Est. Jun 2020
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
1
VXA-CoV2-3.1Phase 21 trial
Active Trials
NCT06672055Active Not RecruitingEst. Nov 2026
Design Therapeutics
1 program
1
ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLSPhase 1/21 trial
Active Trials
NCT04366323CompletedEst. Dec 2021
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19N/A1 trial
Active Trials
NCT04456075Unknown100Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OctapharmaOctagam
VaxartVXA-CoV2-3.1
Design TherapeuticsALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Heidelberg PharmaRisk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Clinical Trials (4)

Total enrollment: 134 patients across 4 trials

NCT04411667OctapharmaOctagam

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

Start: Apr 2020Est. completion: Jun 202034 patients
Phase 4Completed
NCT06672055VaxartVXA-CoV2-3.1

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Start: Oct 2024Est. completion: Nov 2026
Phase 2Active Not Recruiting
NCT04366323Design TherapeuticsALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19

Start: Apr 2020Est. completion: Dec 2021
Phase 1/2Completed
NCT04456075Heidelberg PharmaRisk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19

Start: Apr 2020Est. completion: Apr 2022100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space